Summary
Thirteen patients with advanced head and neck cancer were entered into a phase II study of fludarabine phosphate. Fludarabine phosphate was given by continuous infusion for 5 days, at a starting dose of 20 mg/m2 per day for patients previously treated with one regimen and 25 mg/m2 per day for previously untreated patients; therapy was repeated every 3–4 weeks. Of the 13 patients, 3 had undergone one prior regimen and 10 patients were previously untreated by chemotherapy. No responses were observed. Myelosuppression was the most common toxicity observed. Four patients developed mild nausea, vomiting and seven developed bleeding stomatitis that resolved in one week. In addition, four patients developed headaches which resolved spontaneously. No renal, hepatic, or neurotoxicity was observed. Our study demonstrates that in previously treated and untreated patients, fludarabine phosphate given on this schedule has little activity in patients with advanced head and neck cancer.
Similar content being viewed by others
References
Brink JJ, Le Page GA: Metabolic effects of 9-D-Arabinosylpurines in ascitic tumor cells. Cancer Res 24: 312, 1964
Brockman RW, Schable Jr FM, Montgomery JA: Biologic activity of 9-B-D-arabino-fluranosyl-2-fluoroadenine, a metabolically stable analog of 9-B-D-arabino-furanosyladenine. Biochem Pharmocol 26: 2193, 1977
Tseng WC, Derse D, Cheng YC, Brockman RW, Bennett LL: “Self potentiation” mechanism of 9-B-D-arabinosylfurano-syl-2 fluoradenine. Fed Proc 40: 666, 1971
White L, Shaddix SC, Cheng YC, Brockman RW, Bennet Jr LI: Inhibition of ribonucleotide reductase and DNA polymerase of tumor-cells by 9-B-D-arabinosyl-2-fluoro-adenine-5′ -tri-phosphate (2F-ara-ATP). Proc Am Assoc Cancer Res 22: 33, 1981
Schabel Jr FM: The anti-viral activity of 9-B-D-arabinofuranosyladenine (Ara-A). Chemotherapy 13: 321, 1968
Casper ES, Mittelman A, Kelsen D, Young CW: Phase I clinical trial of fludarabine phosphate (F-ara-AMP). Cancer Chemother Pharmocol 15: 233, 1985
Weiss GB, Metch B, Von Hoff DD, Taylor SA, Saiers JH: Phase II trial of fludarabine phosphate in patients with head and neck cancer: A Southwest Oncology Group Study. Cancer Treat Rep 71: 1313–1314, 1987
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Mittelman, A., Savona, S., Puccio, C. et al. Phase II trial of fludarabine phosphate (F-ara-AMP) in patients with advanced head and neck cancer. Invest New Drugs 8 (Suppl 1), S65–S67 (1990). https://doi.org/10.1007/BF00171986
Issue Date:
DOI: https://doi.org/10.1007/BF00171986